You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lenz H, Parikh A, Spigel DR, et al
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Journal for ImmunoTherapy of Cancer 2024;12:e008409. doi: 10.1136/jitc-2023-008409